NASDAQ:KALV KalVista Pharmaceuticals (KALV) Stock Price, News & Analysis $14.79 +0.40 (+2.78%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$14.54▼$14.9350-Day Range$11.08▼$15.3952-Week Range$7.21▼$16.88Volume226,454 shsAverage Volume555,682 shsMarket Capitalization$632.12 millionP/E RatioN/ADividend YieldN/APrice Target$24.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get KalVista Pharmaceuticals alerts: Email Address KalVista Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside62.3% Upside$24.00 Price TargetShort InterestBearish14.81% of Shares Sold ShortDividend StrengthN/ASustainability-0.79Upright™ Environmental ScoreNews Sentiment-0.19Based on 3 Articles This WeekInsider TradingSelling Shares$439,424 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($3.38) to ($1.50) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.49 out of 5 starsMedical Sector297th out of 936 stocksPharmaceutical Preparations Industry136th out of 436 stocks 3.5 Analyst's Opinion Consensus RatingKalVista Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageKalVista Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.Read more about KalVista Pharmaceuticals' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted14.81% of the outstanding shares of KalVista Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverKalVista Pharmaceuticals has a short interest ratio ("days to cover") of 18.4, which indicates bearish sentiment.Change versus previous monthShort interest in KalVista Pharmaceuticals has recently increased by 7.65%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldKalVista Pharmaceuticals does not currently pay a dividend.Dividend GrowthKalVista Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreKalVista Pharmaceuticals has received a 72.32% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Preclinical research services for physical health" and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for KalVista Pharmaceuticals is -0.79. Previous Next 1.6 News and Social Media Coverage News SentimentKalVista Pharmaceuticals has a news sentiment score of -0.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for KalVista Pharmaceuticals this week, compared to 3 articles on an average week.Search Interest1 people have searched for KALV on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added KalVista Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, KalVista Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $439,424.00 in company stock.Percentage Held by Insiders12.30% of the stock of KalVista Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about KalVista Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for KalVista Pharmaceuticals are expected to grow in the coming year, from ($3.38) to ($1.50) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of KalVista Pharmaceuticals is -4.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of KalVista Pharmaceuticals is -4.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKalVista Pharmaceuticals has a P/B Ratio of 3.04. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about KalVista Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTIWe’re in a code red crisis and 99% of Americans are clueless Folks, it's 2024… Things that we used to rely on - are failing us. Take the phasing out of fossil fuels… Matched with the destruction of oil refineries around the world… And the outright failure of solar and wind technologies… But there is just one solution… And right now governments around the world are stockpiling this resource at the fastest rate in DECADES! And how YOU can prepare for the next 2024 BOOM here! About KalVista Pharmaceuticals Stock (NASDAQ:KALV)KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.Read More KALV Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart KALV Stock News HeadlinesJuly 25 at 2:36 PM | bizjournals.comDrug developer ditches Cambridge for Framingham and triples its spaceJuly 18, 2024 | americanbankingnews.comQ1 2025 EPS Estimates for KalVista Pharmaceuticals, Inc. Decreased by HC Wainwright (NASDAQ:KALV)July 26, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.July 16, 2024 | americanbankingnews.comKalVista Pharmaceuticals (NASDAQ:KALV) Receives "Buy" Rating from HC WainwrightJune 24, 2024 | seekingalpha.comBullish On KalVista Pharmaceuticals: Sebetralstat Nears Approval, Aiming For 2025 LaunchJune 18, 2024 | businesswire.comKalVista Submits New Drug Application to FDA for Sebetralstat as First Oral On-demand Treatment for Hereditary AngioedemaJune 6, 2024 | businesswire.comKalVista Pharmaceuticals Presents Data at Eastern Allergy Conference 2024 and the Japanese Dermatological Association 2024June 6, 2024 | businesswire.comKalVista Pharmaceuticals Presents Data at Eastern Allergy Conference 2024 and the Japanese Dermatological Association 2024July 26, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.June 4, 2024 | businesswire.comKalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 31, 2024 | businesswire.comKalVista Pharmaceuticals Announces New England Journal of Medicine Publishes Oral Sebetralstat Phase 3 Data Demonstrating its Potential to Transform the Treatment Landscape for People with Hereditary AngioedemaMay 24, 2024 | businesswire.comKalVista Pharmaceuticals Announces Ten Abstracts Accepted for Presentation at the European Academy of Allergy and Clinical Immunology Congress 2024May 24, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Aldeyra Therapeutics (ALDX), LAVA Therapeutics (LVTX) and Crinetics Pharmaceuticals (CRNX)May 21, 2024 | finance.yahoo.comBreakeven On The Horizon For KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)May 21, 2024 | businesswire.comKalVista Pharmaceuticals to Present at Upcoming Investor ConferencesMay 12, 2024 | morningstar.comKalVista Pharmaceuticals Inc KALVMay 8, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Pacira Pharmaceuticals (PCRX) and Masimo (MASI)May 1, 2024 | finance.yahoo.comKalVista Pharmaceuticals Highlights Strategic Plans for Coming Fiscal YearSee More Headlines Receive KALV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for KalVista Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings7/11/2024Today7/26/2024Next Earnings (Estimated)9/05/2024Fiscal Year End4/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:KALV CUSIPN/A CIK1348911 Webwww.kalvista.com Phone857-999-0075Fax866-553-3269Employees100Year FoundedN/APrice Target and Rating Average Stock Price Target$24.00 High Stock Price Target$32.00 Low Stock Price Target$20.00 Potential Upside/Downside+62.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($3.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-126,640,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-92.28% Return on Assets-78.12% Debt Debt-to-Equity RatioN/A Current Ratio9.90 Quick Ratio9.90 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.86 per share Price / Book3.05Miscellaneous Outstanding Shares42,740,000Free Float36,999,000Market Cap$632.55 million OptionableOptionable Beta0.91 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMr. Benjamin L. Palleiko (Age 58)CEO & Director Comp: $707.1kDr. Christopher M. Yea Ph.D. (Age 60)Chief Development Officer Comp: $640.23kDr. Edward P. Feener Ph.D. (Age 64)Chief Scientific Officer Comp: $506kMr. Ryan BakerHead of Investor RelationsMr. Brian Krex J.D. (Age 56)General Counsel Jarrod AldomVice President of Corporate CommunicationsMs. Rachel M. MortenSenior Vice President of Regulatory Affairs & QADr. Michael D. Smith Pharm.D. (Age 44)Senior Vice President of Development Dr. Paul K. Audhya M.B.A. (Age 51)M.D., Chief Medical Officer Ms. Nicole Sweeny (Age 48)Chief Commercial Officer More ExecutivesKey CompetitorsArbutus BiopharmaNASDAQ:ABUSAlimera SciencesNASDAQ:ALIMBeyondSpringNASDAQ:BYSIMagenta TherapeuticsNASDAQ:MGTABioCryst PharmaceuticalsNASDAQ:BCRXView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 23,547 shares on 7/26/2024Ownership: 0.317%AlphaCentric Advisors LLCSold 127,500 shares on 7/26/2024Ownership: 0.006%Rosalind Advisors Inc.Bought 50,000 shares on 7/12/2024Ownership: 0.801%Benjamin L PalleikoSold 7,465 sharesTotal: $86,071.45 ($11.53/share)Benjamin L PalleikoSold 21,959 sharesTotal: $258,237.84 ($11.76/share)View All Insider TransactionsView All Institutional Transactions KALV Stock Analysis - Frequently Asked Questions How have KALV shares performed this year? KalVista Pharmaceuticals' stock was trading at $12.25 at the beginning of 2024. Since then, KALV shares have increased by 20.7% and is now trading at $14.79. View the best growth stocks for 2024 here. How were KalVista Pharmaceuticals' earnings last quarter? KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) released its quarterly earnings results on Thursday, July, 11th. The specialty pharmaceutical company reported ($1.02) earnings per share for the quarter, missing analysts' consensus estimates of ($0.73) by $0.29. Who are KalVista Pharmaceuticals' major shareholders? Top institutional shareholders of KalVista Pharmaceuticals include Rosalind Advisors Inc. (0.80%), Bank of New York Mellon Corp (0.32%) and AlphaCentric Advisors LLC (0.01%). Insiders that own company stock include Venrock Healthcare Capital Par, Benjamin L Palleiko, Thomas Andrew Crockett, Edward P Feener, Christopher Yea, Paul K Audhya and Albert Cha. View institutional ownership trends. How do I buy shares of KalVista Pharmaceuticals? Shares of KALV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of KalVista Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that KalVista Pharmaceuticals investors own include Heron Therapeutics (HRTX), Sorrento Therapeutics (SRNE), Cara Therapeutics (CARA), SCYNEXIS (SCYX), TG Therapeutics (TGTX), VBI Vaccines (VBIV) and Aldeyra Therapeutics (ALDX). This page (NASDAQ:KALV) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding KalVista Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share KalVista Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
